Supernus Pharmaceuticals Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Supernus Pharmaceuticals and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Supernus Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Supernus Pharmaceuticals and Johnson & Johnson, as reported by MarketBeat.

Supernus Pharmaceuticals currently has a consensus price target of $27.6667, indicating a potential downside of 2.27%. Johnson & Johnson has a consensus price target of $180.6429, indicating a potential upside of 12.03%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Supernus Pharmaceuticals.

Insider & Institutional Ownership

96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Supernus Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Profitability

This table compares Pfizer and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Pfizer has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Institutional and Insider Ownership

67.4% of Pfizer shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Pfizer and Supernus Pharmaceuticals, as provided by MarketBeat.com.

Pfizer presently has a consensus target price of $38.5714, suggesting a potential upside of 5.39%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 2.27%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Supernus Pharmaceuticals.

Earnings and Valuation

This table compares Pfizer and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Supernus Pharmaceuticals. Pfizer is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Supernus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Merck & Co., Inc. and Supernus Pharmaceuticals' revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Merck & Co., Inc. and Supernus Pharmaceuticals, as reported by MarketBeat.com.

Merck & Co., Inc. presently has a consensus price target of $95.9167, suggesting a potential upside of 25.69%. Supernus Pharmaceuticals has a consensus price target of $27.6667, suggesting a potential downside of 2.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Supernus Pharmaceuticals.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Merck & Co., Inc. beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Valuation and Earnings

This table compares AbbVie and Supernus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Supernus Pharmaceuticals. AbbVie is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for AbbVie and Supernus Pharmaceuticals, as reported by MarketBeat.com.

AbbVie presently has a consensus price target of $115.75, indicating a potential upside of 7.63%. Supernus Pharmaceuticals has a consensus price target of $27.6667, indicating a potential downside of 2.27%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts plainly believe AbbVie is more favorable than Supernus Pharmaceuticals.

Summary

AbbVie beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 0.1% of Eli Lilly and shares are owned by company insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Eli Lilly and and Supernus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly and and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Eli Lilly and and Supernus Pharmaceuticals, as provided by MarketBeat.

Eli Lilly and presently has a consensus target price of $196.40, indicating a potential upside of 6.46%. Supernus Pharmaceuticals has a consensus target price of $27.6667, indicating a potential downside of 2.27%. Given Eli Lilly and's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and is more favorable than Supernus Pharmaceuticals.

Risk & Volatility

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Summary

Eli Lilly and beats Supernus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Supernus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Supernus Pharmaceuticals. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol-Myers Squibb and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bristol-Myers Squibb and Supernus Pharmaceuticals, as provided by MarketBeat.

Bristol-Myers Squibb presently has a consensus target price of $74.6429, suggesting a potential upside of 19.22%. Supernus Pharmaceuticals has a consensus target price of $27.6667, suggesting a potential downside of 2.27%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, equities analysts clearly believe Bristol-Myers Squibb is more favorable than Supernus Pharmaceuticals.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bristol-Myers Squibb beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.